Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ofranergene obadenovec
- Development stage
- Phase 3
- Lead developer
- VBL Therapeutics
- Modality
- Oncolytic Viruses → Oncolytic Therapeutics, Gene Therapies
- Administration
- Intravenous
01
Overview
Ofranergene obadenovec is a non-replicating adenovirus 5 (Ad5, E1-deleted) gene therapy encoding a human Fas-chimera (Fas-c) transgene under the control of a modified murine pre-proendothelin promoter (PPE-1–3x). It is administered intravenously and designed to target tumor vasculature. The drug has a dual mechanism of action: it disrupts tumor neovascularization (vascular disruption) and induces a tumor-directed immune response. Ofranergene obadenovec was developed primarily for anti-cancer indications, including ovarian cancer, glioblastoma, thyroid cancer, colorectal cancer, lung cancer, and malignant melanoma. Its development has been led by VBL Therapeutics and other collaborators. The agent received orphan drug status for ovarian cancer and glioblastoma but has been discontinued in all major indications after not meeting primary endpoints in late-stage clinical trials[1][5][6][8].
- Brand names
- Ofra-Vec
- Other names
- GENETIC VECTOR CONTAINING TUMOR VASCULAR ENDOTHELIUM-DIRECTED CHIMERIC FAS ANTIGEN GENE
02
Targets
TNFRSF1A (Tumor necrosis factor receptor superfamily member 1A)
Beyond the preview
Go deeper on ofranergene obadenovec.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ofranergene obadenovec.